Finding the best radiotherapy dose to use with immunotherapy for early-stage triple-negative breast cancer

Who could benefit from this research

What this research studies

This research aims to improve treatment outcomes for patients with early-stage triple-negative breast cancer (TNBC) by determining the optimal dose of radiotherapy to combine with preoperative immunotherapy and chemotherapy. The study builds on previous findings that showed the addition of pembrolizumab, an immune checkpoint inhibitor, to standard chemotherapy improves patient responses. However, a significant number of patients do not respond to this treatment, highlighting the need for new strategies. By expanding an ongoing clinical trial, the research will test various doses of radiotherapy to find the most effective combination for enhancing patient outcomes.

Why it matters

Where this research is happening

• Univ of North Carolina Chapel Hill
  Chapel Hill, United States Active

Researchers

• Principal investigator: Gupta, Gaorav P. — Univ of North Carolina Chapel Hill
• Study coordinator: Gupta, Gaorav P.

Related research

Other NIH-funded projects on the same topics.

• Best radiation dose with pre-surgery chemo and pembrolizumab for early-stage triple-negative breast cancer

  This project compares different radiation doses given before surgery together with chemotherapy and pembrolizumab for people with early-stage, node-positive triple-negative breast cancer to find the safest and most helpful approach.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10880515

• Shark-Derived Therapy to Target TNBC with Radioactive Treatment

  A new treatment approach uses shark-derived molecules attached to radioactive therapy to target and kill triple-negative breast cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11391249

• Mitochondrial gene therapy plus targeted chemotherapy for triple-negative breast cancer

  A new approach combines modifying cancer cell powerhouses with a targeted chemotherapy strategy to help people with triple-negative breast cancer.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11324279

• Targeting mitochondrial energy in triple-negative breast cancer that remains after chemo

  This work looks at whether blocking a tumor's mitochondrial energy program can help people with triple-negative breast cancer whose tumors remain after chemotherapy.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11238042

• Combining gene therapy and chemotherapy to treat aggressive breast cancer

  This study is exploring a new way to treat triple-negative breast cancer by using a combination of gene therapy and special chemotherapy to target the energy centers of cancer cells, with the hope of making treatments work better and stopping the cancer from becoming resistant to drugs.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11094833

• Understanding how triple negative breast cancer adapts after chemotherapy

  This study is looking at how triple negative breast cancer cells adapt their energy use to survive after chemotherapy, and it aims to find new ways to target these changes to help improve treatment for patients like you.

  NIH research Baylor College of Medicine · Houston, United States · NIH-10988230

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.